Kamada Stock Price, News & Analysis (NASDAQ:KMDA)

$5.16
+0.03 (+0.58 %)
(As of 09/20/2019 04:00 PM ET)
Today's Range
$5.12
Now: $5.16
$5.18
50-Day Range
$5.12
MA: $5.43
$5.74
52-Week Range
$4.63
Now: $5.16
$6.70
Volume5,299 shs
Average Volume57,255 shs
Market Capitalization$207.76 million
P/E Ratio9.38
Dividend YieldN/A
Beta1.19
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KMDA
CUSIPN/A
Phone972-8940-6472

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$114.47 million
Cash Flow$0.6442 per share
Book Value$2.79 per share

Profitability

Net Income$22.30 million

Miscellaneous

Employees408
Market Cap$207.76 million
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable

Receive KMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.


Kamada (NASDAQ:KMDA) Frequently Asked Questions

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) announced its quarterly earnings data on Tuesday, August, 6th. The biotechnology company reported $0.15 EPS for the quarter, beating the Zacks' consensus estimate of $0.14 by $0.01. The biotechnology company earned $35.25 million during the quarter, compared to analyst estimates of $33.86 million. Kamada had a net margin of 21.10% and a return on equity of 23.60%. View Kamada's Earnings History.

When is Kamada's next earnings date?

Kamada is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for Kamada.

What guidance has Kamada issued on next quarter's earnings?

Kamada issued an update on its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $125-130 million, compared to the consensus revenue estimate of $128.49 million.

What price target have analysts set for KMDA?

2 analysts have issued 1-year target prices for Kamada's stock. Their forecasts range from $7.00 to $11.00. On average, they anticipate Kamada's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 74.4% from the stock's current price. View Analyst Price Targets for Kamada.

What is the consensus analysts' recommendation for Kamada?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kamada.

What are Wall Street analysts saying about Kamada stock?

Here are some recent quotes from research analysts about Kamada stock:
  • 1. According to Zacks Investment Research, "Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. " (8/13/2019)
  • 2. HC Wainwright analysts commented, "Our price target of $11/share is based on an equally weighted composite of: (a) $14.26/share, as a 35x multiple of taxed and diluted FY23 GAAP EPS of $0.84 discounted back to and (b) an NPV of $8.1/share (discount rate 12%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of AAT (IV and IH) to achieve peak commercial revenue estimates in our model (due to market size, penetration rates, and/ or pricing); (2) failure of IH-AAT in clinical studies; (3) failure of IH-AAT to secure regulatory approval; and (4) other potential pipeline failures." (8/7/2019)

Has Kamada been receiving favorable news coverage?

Media headlines about KMDA stock have been trending negative recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kamada earned a news impact score of -2.9 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Kamada.

Are investors shorting Kamada?

Kamada saw a decrease in short interest in the month of August. As of August 31st, there was short interest totalling 13,700 shares, a decrease of 20.8% from the July 31st total of 17,300 shares. Based on an average trading volume of 37,800 shares, the short-interest ratio is presently 0.4 days. Currently, 0.1% of the company's shares are sold short. View Kamada's Current Options Chain.

Who are some of Kamada's key competitors?

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Zoetis (ZTS) and Transocean (RIG).

Who are Kamada's key executives?

Kamada's management team includes the folowing people:
  • Mr. Amir London, Chief Exec. Officer (Age 50)
  • Mr. Chaime Orlev, Chief Financial Officer (Age 49)
  • Mr. Eran Nir, VP of Operations & Plant Mang. (Age 46)
  • Mr. David Tsur, Co-Founder & Active Deputy Chairman (Age 68)
  • Dr. Naveh Tov M.D., Ph.D., VP of Clinical Devel. & Medical Director for Pulmonary Diseases (Age 55)

Who are Kamada's major shareholders?

Kamada's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Delek Group Ltd. (2.50%), Acadian Asset Management LLC (2.44%), Renaissance Technologies LLC (1.99%), Ibex Investors LLC (0.68%), Marshall Wace LLP (0.20%) and ARK Investment Management LLC (0.20%).

Which institutional investors are selling Kamada stock?

KMDA stock was sold by a variety of institutional investors in the last quarter, including Ibex Investors LLC and ARK Investment Management LLC.

Which institutional investors are buying Kamada stock?

KMDA stock was bought by a variety of institutional investors in the last quarter, including Delek Group Ltd., Renaissance Technologies LLC, Jane Street Group LLC, BlackRock Inc., Acadian Asset Management LLC, Engine Capital Management LP, Marshall Wace LLP and C M Bidwell & Associates Ltd..

How do I buy shares of Kamada?

Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kamada's stock price today?

One share of KMDA stock can currently be purchased for approximately $5.16.

How big of a company is Kamada?

Kamada has a market capitalization of $207.76 million and generates $114.47 million in revenue each year. The biotechnology company earns $22.30 million in net income (profit) each year or $0.55 on an earnings per share basis. Kamada employs 408 workers across the globe.View Additional Information About Kamada.

What is Kamada's official website?

The official website for Kamada is http://www.kamada.com/.

How can I contact Kamada?

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected]


MarketBeat Community Rating for Kamada (NASDAQ KMDA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  208 (Vote Outperform)
Underperform Votes:  241 (Vote Underperform)
Total Votes:  449
MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe KMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/20/2019 by MarketBeat.com Staff

Featured Article: Resistance Level

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel